# Resmed Inc: Form 10-Q for the period ended Dec 31, 2022

- Company: [Resmed Inc](/companies/rmd.md) (CIK 943819)
- Form: 10-Q
- Filed: 2023-01-27
- Accepted by EDGAR: Jan 26, 2023, 18:09 ET
- Period: 2022-12-31
- Accession: 0000943819-23-000003
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/943819/000094381923000003/rmd-20221231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/943819/000094381923000003/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-10-01 to 2022-12-31 | $1.03bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-07-01 to 2022-12-31 | $1.98bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-10-01 to 2022-12-31 | $454.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2022-07-01 to 2022-12-31 | $863.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-10-01 to 2022-12-31 | $579.7m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-07-01 to 2022-12-31 | $1.12bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-10-01 to 2022-12-31 | $69.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-07-01 to 2022-12-31 | $133.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2022-10-01 to 2022-12-31 | $211.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2022-07-01 to 2022-12-31 | $404.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-10-01 to 2022-12-31 | $280.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-07-01 to 2022-12-31 | $555.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-10-01 to 2022-12-31 | $48.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-07-01 to 2022-12-31 | $100.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-10-01 to 2022-12-31 | $224.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-07-01 to 2022-12-31 | $435.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-10-01 to 2022-12-31 | $1.53 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-07-01 to 2022-12-31 | $2.95 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-10-01 to 2022-12-31 | $1.53 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-07-01 to 2022-12-31 | $2.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-10-01 to 2022-12-31 | 147,405,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-07-01 to 2022-12-31 | 147,367,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-07-01 to 2022-12-31 | $173.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-07-01 to 2022-12-31 | $56.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2022-07-01 to 2022-12-31 | $128.9m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2022-12-31 | $253.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $2.33bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $6.68bn | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $732.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $2.94bn | us-gaap:Liabilities |
| Long-term debt | at 2022-12-31 | $1.79bn | us-gaap:LongTermDebt |
| Short-term borrowings | at 2022-12-31 | $9.9m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2022-12-31 | $3.74bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,344 characters.

**Purchases of equity securities.** On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program.

We temporarily suspended our share repurchase program due to recent acquisitions and as a response to the COVID-19 pandemic. As a result, we did not repurchase any shares during the three months ended December 31, 2022. However, there is no expiration date for this program, and we may, at any time, elect to resume the share repurchase program as the circumstances allow. Since the inception of the share buyback programs, we have repurchased 41.8 million shares at a total cost of $1.6 billion. At December 31, 2022, 12.9 million additional shares of common stock can be repurchased under the approved share repurchase program.

## Controls and procedures

As filed, 1,803 characters.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2022.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 393 characters.

The discussion of our business and operations should be read together with the risk factors and contained in our annual report on Form 10-K for the fiscal year ended June 30, 2022, which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. As of December 31, 2022, there have been no further material changes to such risk factors.

Filed Jan 27, 2023.
Source: SEC EDGAR, the filing index for accession 0000943819-23-000003. Last ingested by Listed: Nov 14, 2026, 17:21 ET. No prices; not investment advice.
